Navigation Links
PROLOR Biotech To Present New Data On Its Long-Acting Human Growth Hormone And Long-Acting Oxyntomodulin At ENDO 2013
Date:6/13/2013

in a Phase IIl clinical trial.  It also is developing long-acting versions of factor VIIa and factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, all of which are in preclinical development.  For more information, visit www.prolor-biotech.com.

Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would", "intends," "estimates," "suggests," "has the potential to" and other words of similar meaning, including statements regarding the results of current clinical studies and preclinical experiments and the effectiveness of PROLOR's long-acting protein programs, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect PROLOR's business and prospects, including the risks that PROLOR may not succeed in generating any revenues or developing any commercial products, including any long-acting versions of human growth hormone, erythropoietin, interferon beta, GLP-1 and other products; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from Israel's Office of the Chief Scientist is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ m
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of PROLOR Biotech, Inc. in Connection with the Sale of the Company to OPKO Health, Inc.
2. Law Office of Brodsky & Smith, LLC Announces Investigation of PROLOR Biotech, Inc.
3. OPKO Health To Acquire PROLOR Biotech
4. PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
5. PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Pediatric Endocrinology Meeting
6. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
7. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
8. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
9. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
10. MedReps.com Report Shows Biotech Workers Earn the Most in Medical Sales
11. Biotechnology Master’s at UMBC Shady Grove - Virtual Info Session to Be Held on June 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... The fully automated supercritical fluidic ... sequentially analyze up to 48 samples utilizing automatic ... of targets by mass spectrometry. , The ... measurement requirements of a wide range of applications, ... and search for disease biomarkers, additives in forming ...
(Date:2/27/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... with patients and health care advocates in the United ... Day®. Rare Disease Day is dedicated to elevating ... the special challenges faced by patients with rare diseases ... proud to stand alongside patients and caregivers representing the ...
(Date:2/26/2015)... N.J. , Feb. 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript,s trade secrets, and that it improperly ... entered an order denying motions for judgment notwithstanding the ...
(Date:2/26/2015)... 26, 2015   Regulus Therapeutics Inc . (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, today ... and Chief Executive Officer of Regulus, will present a ... Annual Healthcare Conference on Wednesday, March 4, 2015 ... at the Boston Marriott Copley Place.  ...
Breaking Biology Technology:Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
... Jan. 17 NEXCORE Technology,Inc, a world-class original ... the intellectual property rights for the,development of a ... new system provides significantly greater control over the,inflow/outflow ... on the system are held by Drs. Atul ...
... for Common Document Types Broadens Project Coalition with Addition ... A-Life Medical, QuadraMed, Misys Healthcare, CHICAGO, Jan. 17 ... Types (CDA4CDT) project starts 2008 on a strong,note adding ... 3M Health Information Systems joined in the fall of ...
... MADISON, N.J., Jan. 17 Quest Diagnostics,Incorporated (NYSE: ... information and services, announced that it will report results,for ... and provide,financial guidance for 2008 on February 21, 2008, ... The company is rescheduling its report of fourth quarter ...
Cached Biology Technology:NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System 2New Benefactors Show Support for CDA4CDT: 2New Benefactors Show Support for CDA4CDT: 3New Benefactors Show Support for CDA4CDT: 4New Benefactors Show Support for CDA4CDT: 5New Benefactors Show Support for CDA4CDT: 6New Benefactors Show Support for CDA4CDT: 7Quest Diagnostics Sets New Date to Report Fourth Quarter and Full Year 2007 Results 2Quest Diagnostics Sets New Date to Report Fourth Quarter and Full Year 2007 Results 3
(Date:2/5/2015)... 2015   Epic Sciences , a precision diagnostics company ... Murali Prahalad , Ph.D., president and CEO, is scheduled ... (PMWC) 2015: Silicon Valley, which is taking place at the ... on January 26-28, 2015. Dr. Prahalad ... Biomarkers." Last year, Epic Sciences was a finalist in the ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... the upcoming RedChip Global Online CEO Conference on January ... Gino Pereira , CEO of NXT-ID will ... lead product, the Wocket smart wallet and its full ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "Biometrics - A Global Market Overview" report to their ... technology is to ensure that an individual is who she/he ... may make use of a person,s unique physical characteristics, such ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... University scientists have defined a hidden second option plants ... be the first step in boosting plants, nutritional value ... phenylalanine is required to build proteins and is a ... plants, including lignin, which allows plants to stand upright ...
... negative emotions they often use spatial metaphors. A happy person is ... in the dumps. Some researchers believe these metaphors are a clue ... spatial words to talk about emotional states, we also use spatial ... To test this link between vertical space and emotion, in ...
... Human Frontier Science Program Organization (HFSPO) is pleased to ... postdoctoral fellowships, career development awards and research grants. HFSP ... selection in a global competition. The names are available ... HFSP postdoctoral fellowships are given to young scientists ...
Cached Biology News:Second plant pathway could improve nutrition, biofuel production 2To remember the good times, reach for the sky 22010 Human Frontier Science Program awards announced 2
... microarrays containing peptidomimetics built on the ... synthesis platform. These microarrays are available ... Peptide Microarray Service. Custom ... completely customer specified. Thousands of customer ...
... you can identify and characterize high-value, low-abundant ... The Agilent Multiple Affinity Removal System allows ... from human serum, plasma, CSF samples and ... this revolutionary system, you can: ...
... Kit contains in vitro synthesized, polyadenylated transcripts ... probes on Agilents microarrays, with minimal self- ... positive microarray control in the hybridization protocol. ... a required component of the Agilent One-Color ...
... mouse-click image analysis software for microarray ... the solution for high quality and ... is empowered with VigeneTechs robust algorithms, ... 2D-curve fitting background correction and dust ...
Biology Products: